Collegium Pharmaceutical, Inc. - COLL STOCK NEWS

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the publication of a study titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment,” in the Journal of Pain Research. The study emphasizes the importance of monitoring real-world data on the abuse and misuse of its products. Richard Malamut, M.D., highlighted the need for the medical community to access these data to make informed treatment decisions. However, the study underscores that Xtampza ER still carries a high potential for addiction, abuse, and misuse.

Collegium Pharmaceutical, a specialty pharmaceutical company focused on responsible pain management, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 PM ET. The event will feature a fireside chat format, and the presentation will be accessible via live webcast on the company’s investor website. A replay will be available for about 30 days post-event. Collegium's headquarters is located in Stoughton, Massachusetts, and they aim to lead in pain management solutions.

Collegium Pharmaceutical, Inc. reported a net income of $15.7 million and Adjusted EBITDA of $45.3 million for Q1 2021. The company raised its full-year guidance for Nucynta franchise revenues from $175-$185 million to $185-$195 million and Adjusted EBITDA from $160-$170 million to $170-$180 million. Colleen Tupper has been appointed as the new CFO, effective May 24, 2021, succeeding Paul Brannelly. Xtampza ER's market share grew to 30.6%, supported by exclusive formulary wins. Collegium was named a 2021 Top Workplaces USA Company.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call scheduled for May 6, 2021, at 4:30 p.m. ET. During this call, the company will discuss its financial results and provide a corporate update.

Investors can access the call by dialing (877) 407-8037 (U.S.) or (201) 689-8037 (International), referencing the "Collegium Pharmaceutical Q1 2021 Earnings Call." An audio webcast will be available on the company's website, with a replay accessible two hours post-event.

Collegium Pharmaceutical reported its 2020 financial results, marking its first full year of profitability, driven by Xtampza ER revenue growth and the acquisition of the Nucynta franchise. For the fourth quarter, net income reached $7.0 million compared to a $2.2 million loss in the same quarter of 2019. Xtampza ER generated $30.8 million in revenue, up 12% year-over-year, while Nucynta revenues fell 3% to $45.5 million. The company has reiterated its 2021 financial guidance, projecting Xtampza ER revenues between $155 million and $165 million.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call scheduled for February 25, 2021, at 4:30 p.m. Eastern Time. The call will cover the Company’s financial results and provide a corporate update.

To participate, call (877) 407-8037 (U.S.) or (201) 689-8037 (International), referencing the “Collegium Pharmaceutical Q4 2020 Earnings Call.” A replay will be available on the Company’s website shortly after the event.

Collegium Pharmaceutical (Nasdaq: COLL) announced its financial guidance for 2021, projecting Xtampza ER revenues between $155 million and $165 million and Nucynta franchise revenues between $175 million and $185 million. Adjusted EBITDA is expected between $160 million and $170 million, with total operating expenses projected between $125 million and $135 million. The company aims to leverage its cost structure and generate significant cash flow from operations while focusing on maximizing the potential of its pain management portfolio.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong Q3 2020 results, achieving record net income of $11.3 million and generating $34.2 million in cash flow from operations. Xtampza ER revenues rose 21% year-over-year to $32.1 million, while Nucynta revenues were $47.1 million. Operating expenses decreased by 12%, enhancing profitability, as reflected in an adjusted EBITDA of $41.8 million. Collegium secured exclusive formulary access for Xtampza ER with a national Medicare Part D plan, covering over 92 million lives, and settled patent litigation with Teva, allowing its generic launch in 2033.

Collegium Pharmaceutical announced the publication of a postmarketing analysis titled “Misuse, Abuse and Diversion of Xtampza ER,” featured in Pain Medicine. This study highlights that, despite a 50-fold increase in prescriptions for Xtampza ER following its launch, incidents of misuse, abuse, and diversion remained low. The analysis utilized RADARS® data to compare Xtampza ER to other opioid formulations. The company emphasized its commitment to ongoing studies and surveillance to contribute to the understanding of abuse-deterrent formulations.